AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 105 Posts
1 2 3 ... 7
AstraZeneca: 4% Dividend Yield And A Pipeline To Emerging Market Growth
Article By: SureDividend Thursday, June 15, 2017 11:35 AM EDT
AstraZeneca’s strong pipeline and heavy presence in the emerging markets lay the groundwork for future growth.
In this article: AZN Also: JNJ, ABT
AstraZeneca Enters Agreement With Grunenthal To Divest Rights To Zomig
Article By: The Fly Wednesday, June 7, 2017 12:10 PM EDT
AstraZeneca announced that it has entered an agreement with Grunenthal for the global rights to Zomig outside Japan.
In this article: AZN, IPXL
Week In Review: Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
Article By: ChinaBio® Today Saturday, May 20, 2017 11:46 AM EDT
Shanghai Pharma may bid $4 billion to acquire Stada Arzneimittel, a German generic drugmaker. Stada has already accepted a similar offer from a consortium formed by two private equity firms -- Bain and Cinven.
In this article: AZN, LLY
E AstraZeneca Achieves Positive Phase 3 Results In Late Stage Cancer Trial
Article By: Terry Chrisomalis Sunday, May 14, 2017 3:52 AM EDT
On Friday, AstraZeneca announced that it had achieved positive results in a phase 3 lung cancer study. The key drug used in the trial, Imfinzi, was shown to greatly cut the risk of death in lung cancer patients.
In this article: AZN Also: MRK
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
9 Blockbuster Drugs Making Their Debut In 2017; Total Revenue Expected To Be $16B By 2021
Article By: Lorimer Wilson Tuesday, April 11, 2017 11:56 PM EDT
It is always interesting to see what analysts believe the big new drugs of the year are going to be worth 5 years down the road and Clarivate Analytics has listed the 9 blockbusters their analysts expect to see approved by the FDA this year.
FDA Nixes Merck’s Request To Have Januvia Cardio Safety Data On Its Label
Article By: Lorimer Wilson Friday, April 7, 2017 12:10 PM EDT
Merck wanted to state on the label of their diabetes drug Januvia that patients could take it without raising their risk for cardio complications to distinguish themselves from same-class rivals like Onglyza, which has risks. FDA has nixed the idea.
In this article: AZN, MRK
Week In Review: Beijing's Creat Offers $1.3 Billion For Biotest Of Germany
Article By: ChinaBio® Today Saturday, April 1, 2017 12:27 PM EDT
Creat Group, a Beijing investment firm, has bid to acquire German blood plasma products maker Biotest for $1.3 billion (including debt).
In this article: AZN, JD
AstraZeneca Plc Receives Key Lung Cancer Drug Approval In China
Article By: Lorimer Wilson Saturday, March 25, 2017 11:58 AM EDT
AstraZeneca plc disclosed Friday via its official WeChat account that a key lung cancer drug has received approval from Chinese regulators, opening up a potentially very lucrative new market in a country where millions suffer from the disease.
In this article: AZN
AstraZeneca & Valeant Facing New Competition In The Opioid-Induced Constipation Arena
Article By: Lorimer Wilson Friday, March 24, 2017 7:48 PM EDT
AstraZeneca & Valeant have been battling it out in the opioid-induced constipation arena with movantik and relistor, respectively, since winning their FDA approvals back in September 2014. Now there’s a third competitor prepping to jump into the mix.
In this article: AZN, VRX, SGIOF
Who Are The Next Acquisition Targets In Dermatology?
Article By: Ari Zoldan Wednesday, March 22, 2017 8:25 AM EDT
Specialty pharmaceuticals is a highly dynamic sector with robust stock valuations and an active mergers & acquisition market. One of the most attractive areas for investment is dermatology.
AstraZeneca Reports Positive Phase 2 Results For Cancer Drug
Article By: KKD Healthcare Analytics Friday, February 17, 2017 12:32 PM EDT
The company stock has gained over 5 percent this year so far. Its 12 months performance is a little shaky as the stock lost 3 percent of its value during this time period.
In this article: AZN
Week In Review: China To Add 300 Drugs To National Reimbursement Drug List
Article By: ChinaBio® Today Saturday, February 4, 2017 1:21 PM EDT
According to sources, China is getting close to announcing a revised National Reimbursement Drug List, the group of drugs covered by China's national insurance plan. 130 will be chemical drugs and the rest will be traditional Chinese medicines.
In this article: AZN, GSK, FGEN
Cempra Plunges To 52-Week Low, Shire Drug Label Expanded
Article By: Arpita Dutt Friday, December 30, 2016 10:33 AM EDT
It was a relatively slow week for pharma stocks though a couple of companies suffered regulatory setbacks with the FDA issuing complete response letters (CRLs) for their regulatory applications.
In this article: AMPH, AZN, BMY, CEMP, MRK, MYL, SHPG
Week In Review: JHL Biotech Signs $257 Million Biosimilar Deal With Sanofi
Article By: ChinaBio® Today Saturday, December 10, 2016 12:44 PM EDT
JHL Biotech, a Taiwan-China biologics company, signed a $257 million partnership agreement that gives Sanofi rights to market a JHL clinical-stage rituximab biosimilar, initially for China.
In this article: AZN, NVS, SNY, CGIX, BGNE
1 to 16 of 105 Posts
1 2 3 ... 7